OA11235A - Quatenary ammonium compounds as tachykinin antagonists - Google Patents

Quatenary ammonium compounds as tachykinin antagonists Download PDF

Info

Publication number
OA11235A
OA11235A OA9900281A OA9900281A OA11235A OA 11235 A OA11235 A OA 11235A OA 9900281 A OA9900281 A OA 9900281A OA 9900281 A OA9900281 A OA 9900281A OA 11235 A OA11235 A OA 11235A
Authority
OA
OAPI
Prior art keywords
compound
phenyl
ch3so3
fluoro
dichlorophenyl
Prior art date
Application number
OA9900281A
Other languages
English (en)
Inventor
Dacid Alker
Christopher John Burns
Sandra Marina Monaghan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11235A publication Critical patent/OA11235A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
OA9900281A 1997-06-18 1999-12-15 Quatenary ammonium compounds as tachykinin antagonists OA11235A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712882.1A GB9712882D0 (en) 1997-06-18 1997-06-18 Quaternary ammonium compounds

Publications (1)

Publication Number Publication Date
OA11235A true OA11235A (en) 2003-07-09

Family

ID=10814535

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900281A OA11235A (en) 1997-06-18 1999-12-15 Quatenary ammonium compounds as tachykinin antagonists

Country Status (43)

Country Link
US (2) US6207678B1 (is)
EP (1) EP0994876B1 (is)
JP (1) JP3280993B2 (is)
KR (1) KR100345389B1 (is)
CN (1) CN1199971C (is)
AP (1) AP947A (is)
AR (1) AR012249A1 (is)
AT (1) ATE275564T1 (is)
AU (1) AU726027B2 (is)
BG (1) BG63341B1 (is)
BR (1) BR9810619A (is)
CA (1) CA2291975C (is)
CO (1) CO4940478A1 (is)
DE (1) DE69826129T2 (is)
DZ (1) DZ2524A1 (is)
EA (1) EA002424B1 (is)
ES (1) ES2227856T3 (is)
GB (1) GB9712882D0 (is)
HN (1) HN1998000087A (is)
HR (1) HRP980337B1 (is)
HU (1) HUP0003962A3 (is)
ID (1) ID23410A (is)
IL (2) IL155621A0 (is)
IS (1) IS5269A (is)
MA (1) MA26509A1 (is)
MY (1) MY136376A (is)
NO (1) NO995782L (is)
NZ (1) NZ501286A (is)
OA (1) OA11235A (is)
PA (1) PA8452501A1 (is)
PE (1) PE80099A1 (is)
PL (1) PL189557B1 (is)
PT (1) PT994876E (is)
SI (1) SI0994876T1 (is)
SK (1) SK283346B6 (is)
TN (1) TNSN98089A1 (is)
TR (1) TR199903135T2 (is)
TW (1) TW479055B (is)
UA (1) UA62966C2 (is)
UY (1) UY25045A1 (is)
WO (1) WO1998057972A1 (is)
YU (1) YU64699A (is)
ZA (1) ZA985239B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043031A4 (en) * 1997-12-26 2007-05-02 Astellas Pharma Inc MEDICAL COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
WO2001095904A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
US6656953B2 (en) * 2000-12-06 2003-12-02 Sepracor Inc. 4,4-Disubstituted piperidines, and methods of use thereof
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
AU2005243153A1 (en) * 2004-05-07 2005-11-24 Janssen Pharmaceutica N.V. Scalable synthesis of imidazole derivatives
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991201A (en) 1974-06-27 1976-11-09 Janssen Pharmaceutica N.V. 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
HRP980337A2 (en) 1999-02-28
BG63341B1 (bg) 2001-10-31
DZ2524A1 (fr) 2003-02-01
ID23410A (id) 2000-04-20
KR100345389B1 (ko) 2002-07-24
MY136376A (en) 2008-09-30
PT994876E (pt) 2005-01-31
UA62966C2 (en) 2004-01-15
GB9712882D0 (en) 1997-08-20
PL189557B1 (pl) 2005-08-31
JP3280993B2 (ja) 2002-05-13
IS5269A (is) 1999-11-23
US6380396B1 (en) 2002-04-30
NO995782L (no) 2000-02-16
HRP980337B1 (en) 2003-02-28
MA26509A1 (fr) 2004-12-20
UY25045A1 (es) 2000-09-29
IL155621A0 (en) 2003-11-23
BR9810619A (pt) 2000-09-12
PL337713A1 (en) 2000-08-28
IL133079A (en) 2004-06-01
EA002424B1 (ru) 2002-04-25
JP2000513030A (ja) 2000-10-03
EA199900986A1 (ru) 2000-06-26
KR20010013909A (ko) 2001-02-26
AP9801262A0 (en) 1998-06-30
AP947A (en) 2001-03-08
CN1199971C (zh) 2005-05-04
ZA985239B (en) 1999-12-17
TNSN98089A1 (fr) 2005-03-15
IL133079A0 (en) 2001-03-19
NO995782D0 (no) 1999-11-25
WO1998057972A1 (en) 1998-12-23
CA2291975C (en) 2004-02-10
SI0994876T1 (en) 2005-02-28
TR199903135T2 (xx) 2000-04-21
CA2291975A1 (en) 1998-12-23
PE80099A1 (es) 1999-08-25
HUP0003962A3 (en) 2001-12-28
TW479055B (en) 2002-03-11
NZ501286A (en) 2000-07-28
PA8452501A1 (es) 2000-05-24
ATE275564T1 (de) 2004-09-15
SK174499A3 (en) 2001-05-10
AU726027B2 (en) 2000-10-26
HN1998000087A (es) 1998-10-22
ES2227856T3 (es) 2005-04-01
CN1260795A (zh) 2000-07-19
US6207678B1 (en) 2001-03-27
AU8215398A (en) 1999-01-04
EP0994876B1 (en) 2004-09-08
CO4940478A1 (es) 2000-07-24
SK283346B6 (sk) 2003-06-03
HUP0003962A2 (hu) 2001-04-28
AR012249A1 (es) 2000-09-27
EP0994876A1 (en) 2000-04-26
DE69826129D1 (de) 2004-10-14
BG103919A (en) 2001-07-31
DE69826129T2 (de) 2005-09-22
YU64699A (sh) 2002-06-19

Similar Documents

Publication Publication Date Title
RU2150468C1 (ru) Производные (азетидин-1-илалкил)лактамов, фармацевтическая композиция на их основе и способ лечения человека, при котором заболевание лечат посредством продуцирования антагонистического действия на тахикинин, действующий в человеческом nк1-, nк2- и nк3-рецепторе или в их сочетании
JP2500280B2 (ja) イミダゾ―ル、トリアゾ―ル及びテトラゾ―ル誘導体
EP0824098B1 (en) 4-hydroxy-piperidine derivatives
WO1997019942A1 (en) 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists
RU2158264C2 (ru) 3-азетидинилалкилпиперидины или пирролидины в качестве антагонистов тахикинина, способы их получения, промежуточные соединения, фармацевтическая композиция на их основе и способ лечения
US20040132710A1 (en) Lactams as tachkinin antagonists
US5973156A (en) Piperidine and tetrahydropyridine derivatives
SK164297A3 (en) 1,6-disubstituted isochromans for treatment of migraine headaches
US6380396B1 (en) Quaternary ammonium compounds
US5981529A (en) Substituted indolylpropyl-piperazine derivatives as 5-HT1D α agonists
US6518282B1 (en) 4-Arylpiperidine derivatives for the treatment of pruritus
US5925638A (en) Substituted 1-indolylpropyl-4-benzylpiperazine derivatives
MXPA99012096A (en) Quaternary ammonium compounds as tachykinin antagonists
CZ453499A3 (cs) Kvarterní amonné sloučeniny jako antagonisty tachykininu
MXPA00005228A (en) 4-arylpiperidine derivatives for the treatment of pruritus
MXPA99005176A (en) Piperidones as tachykinin antagonists
JPH07179337A (ja) アルキルーフェノキシアルキルアミン誘導体を有効成分とする抗血栓剤